Ferreira 2007.

Methods	No current or past use of hypolipidaemic drugs in the past 6 months 8‐Week before‐and‐after trial
Participants	91 women with systemic lupus erythematosus; three were excluded for reasons not related to the therapeutic protocol; 88 participants completed the study 64 participants received atorvastatin, 24 control participants received no atorvastatin Exclusion criteria: menopausal status, diabetes mellitus, serum creatinine > 1.2 mg/dL, pregnancy, smoking status in the past 12 months, family history of CHD, skeletal myopathic disease, elevated CK, hepatic disease, use of cyclosporine Atorvastatin baseline TC: 4.20 mmol/L (162 mg/dL) Atorvastatin baseline LDL‐C: 2.38 mmol/L (92 mg/dL) Atorvastatin baseline HDL‐C: 1.22 mmol/L (47 mg/dL) Atorvastatin baseline TG: 1.30 mmol/L (50 mg/dL)
Interventions	Atorvastatin 20 mg/d
Outcomes	Per cent change from baseline at 8 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study appears to be free of other sources of bias